Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005–2016
There are no pharmacovigilance studies on adverse event (AE) data for tumour necrosis factor alpha (TNFα) inhibitors in South Korea. We analysed AEs induced by adalimumab, infliximab, and etanercept
We used data from the Korea Institute of Drug Safety and Risk Management–Korea Adverse Events Reporting System Database (KIDS-KD) collected between 2005 and 2016. We used three different signal detection methods: proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). The drug was compared with drug labels in the USA and Korea. Logistic regression analysis identified AEs that are more likely to occur with drug use.
Of the 5594 AEs identified, 350, 452, and 71 were related to adalimumab, infliximab, and etanercept, respectively. We identified seven new signals, which were not listed on drug labels in either Korea or the USA, for AEs associated with the study drugs: two for adalimumab (medication error and drug failure), two for infliximab (palpitation and temperature sensation change), and three for etanercept (hyperkeratosis, acne, and thyroid neoplasm malignant). Injection site pain (OR 6.14, 95% CI 1.15–32.74) and alopecia (OR 4.54, 95% CI 1.16–17.77) for adalimumab, chest pain (OR 6.01, 95% CI 1.35–26.77) for infliximab, and uveitis (OR 10.11, 95% CI 1.13–90.77) for etanercept were more likely to be reported in patients with each TNFα inhibitor than in those without, respectively.
• Large-scale spontaneous AE reporting data and data mining techniques are useful for detecting signals of rare AEs as well as common AEs induced by drugs.
• Drug labels should be updated to reflect signals that are newly discovered by continuous monitoring.
KeywordsData mining Drug-AE Drug label KIDS-KD Signal detection Tumour necrosis factor-α inhibitors
Compliance with ethical standards
This study was approved by the Institutional Review Board of Sungkyunkwan University in Korea (SKKU-IRB-2018-02-005).
Informed consent was waived by the Institutional Review Board for this study because all personal information on patients was anonymous.
- 5.Kahn R, Berthold E, Gullstrand B, Schmidt T, Kahn F, Geborek P, Saxne T, Bengtsson AA, Mansson B (2016) Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis. Acta Paediatrica (Oslo, Norway : 1992) 105(4):427–432CrossRefGoogle Scholar
- 6.Taurone S, Bianchi E, Attanasio G, Di Gioia C, Ierino R, Carubbi C, Galli D, Pastore FS, Giangaspero F, Filipo R, Zanza C, Artico M (2015) Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Molecular Medicine Reports 12(1):737–745CrossRefGoogle Scholar
- 11.Kirkham B (2016) Tumor necrosis factor-alpha inhibitors: an overview of adverse effects. https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects
- 12.Mendes D, Alves C, Batel-Marques F (2014) Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. Journal of Clinical Pharmacy and Therapeutics 39(3):307–313CrossRefGoogle Scholar
- 13.Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y, Hatahira H, Abe J, Fukuda A, Naganuma M, Kinosada Y, Nakamura M (2017) Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. Int J Med Sci 14(2):102–109CrossRefGoogle Scholar
- 14.Organization WH (2018) Cauality Assessment. https://wwww.hoint/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed 5 May 2018
- 23.DailyMed [Available from: https://dailymed.nlm.nih.gov/dailymed/index.cfm. Accessed 15 June 2018
- 25.Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, Koenig AS, Freundlich B (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology 28(2):238–245PubMedGoogle Scholar
- 26.Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295(19):2275–2285CrossRefGoogle Scholar
- 27.Cutroneo PM, Isgro V, Russo A, Ientile V, Sottosanti L, Pimpinella G, Conforti A, Moretti U, Caputi AP, Trifiro G (2014) Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. Drug Safety 37(11):961–970CrossRefGoogle Scholar
- 29.Garcia-Lagunar MH, Gutierrez-Civicos MR, Garcia-Simon MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P, Garcia-Marquez A, Munoz-Garcia I, Viney AC (2017) Reasons for discontinuation and adverse effects of TNFalpha inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. The Annals of Pharmacotherapy 51(5):388–393CrossRefGoogle Scholar
- 35.The European Medicine Agency Homepage (2018) https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-newrestrictions-use-following-review. Accessed 4 May 2019